Minimal Residual Disease Testing for Cancer
Customize your policy alerts
Sign up for devoted_health Policy UMGT.CL.0027 alerts
Get alerted when Policy UMGT.CL.0027 changes without checking for updates manually.
Monitor payer policy activity
This policy governs medical necessity and coverage of minimally invasive molecular DNA and RNA tests used to detect minimal residual disease in patients with a personal history of solid tumors or hematologic malignancies. It applies to all Devoted Health plans and requires testing to align with applicable clinical guidelines and CMS coverage requirements.
Coverage added for Merkel cell carcinoma and one-time post-surgery MRD testing for stage 2 or 3 colon cancer.
Coverage for chronic myeloid leukemia and leptomeningeal cancer was removed.
Coverage added for qualifying muscle-invasive bladder cancer after cystectomy.
Muscle-invasive bladder cancer criteria were updated during the August 2026 ad hoc review.
Testing frequency and reimbursement were clarified to follow applicable CMS Billing and Coding Articles and related LCD criteria.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.